is srpt smart to buy

**Sarepta Therapeutics (SRPT) appears to be a smart buy** based on several factors:

1. **Positive Analyst Ratings and Price Targets**: The consensus rating for SRPT is a "Buy" with an average price target of $182.77. This suggests that analysts are optimistic about the stock's future performance.

2. **Strong Financial Performance**: The company has shown a significant year-on-year total revenue growth rate of 63.1% and a net income of $36.12 million. This indicates a strong financial performance and potential for future growth.

3. **Momentum and Analyst Optimism**: There is growing optimism among analysts about the company's earnings prospects, as evidenced by strong agreement among them in revising EPS estimates higher. This optimism could lead to increased investor confidence.
4. **Recent Insider Activity**: While there have been insider sales, the stock is still considered fairly valued by some analysts. Insider activity can be a signal to investors about the confidence that insiders have in the company's future.
5. **Technical Indicators**: The stock's technical indicators such as MACD, RSI, and KDJ are not available, but the absence of these indicators may also mean that the stock is not currently overbought or oversold, which could be a good sign for investors.
6. **Market Performance**: SRPT has shown strong performance with a 30.53% increase over the past quarter and a 42.3% gain in the last year, outperforming the S&P 500's respective movements. This indicates a strong market performance and potential for continued growth.
7. **Institutional Confidence**: Institutional investors are known to have a deep understanding of a company's fundamentals and often lead the market. SRPT has a moderate institutional position with 14 buy ratings and 5 hold ratings. This suggests that a significant number of institutions are confident in the company's future.

In conclusion, SRPT's strong financial performance, positive analyst ratings, and recent momentum make it a smart buy for investors who are comfortable with the biotechnology sector's inherent risks. However, it's important to consider your own investment strategy, risk tolerance, and the potential volatility of the biotechnology market before making any investment decisions.